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INTRODUCTION
 Worldwide, endometrial carcinoma is the second 
most common female genital tract cancer, after 
cervical cancer. In Asia, it is the most common 
female genital tract malignancy, accounting for 
nearly 41% of all new gynaecological cancers. In 
Pakistan, endometrial cancer is the third most 
common genital tract malignancy, after cancer of 
the cervix or ovary. Its incidence is rising because 
of the increased life expectancy and prevalence of 
obesity observed in the recent years.
 Most cases (95%) of uterine carcinoma occur in 
women over 40 years of age, usually in the sixth 
and seventh decades of life. The overall lifetime 
risk of developing endometrial carcinoma is 2.5%.1 
Seventy-five percent of endometrial carcinomas is 
confined to the uterus (clinical stage 1) at the time 
of diagnosis. Endometrial carcinoma generally 
carries an excellent prognosis in terms of curability 
and recurrence. There is an increasing emphasis 
on surgico-pathologic staging, which includes the 
1. Dr. Uzma Chishti,
 Senior Instructor,
2. Dr. Aliya B. Aziz,
 Assistant Professor,
3. Dr. Munazza Akhtar,
 Senior Instructor,
1-3: Department of Obstetrics and Gynaecology,
 Aga Khan University Hospital, Karachi, Pakistan.
 Correspondence:
 Dr. Aliya B. Aziz,
 E-mail: aliya.aziz@aku.edu
  * Received for Publication: March 2, 2015
  * Revision Received: April 20, 2015
  * Revision Accepted: April 28, 2015
Original Article
Selective lymphadenectomy in endometrial cancer: 
Retrospective analysis of morbidity and survival 
data at a tertiary care centre
Uzma Chishti1, Aliya B. Aziz2, 
Munazza Akhtar3, Sana Sheikh4
ABSTRACT
Objective: To compare perioperative morbidity and survival data between patients with early-stage 
endometrial cancer who did or did not undergo selective lymphadenectomy.
Methods: Retrospective analysis of 180 patients with early-stage endometrial carcinoma treated between 
1999 and 2008 was performed in Aga Khan University Hospital, Karachi, Pakistan.
Results: Data from 180 patients were analysed. The selective lymphadenectomy group contained 108 
women (60%) and the no lymphadenectomy group contained 72 women (40%). The median number of lymph 
nodes removed was 9. The mean age and extent of disease, as assessed by staging, tumour size, myometrial 
invasion, and lymphovascular invasion were comparable between groups. Upstaging of the disease to stage 
3 and 4 occurred in 11% of patients in the lymphadenectomy group. There were no significant differences 
in the medical or surgical complications between groups. At a median follow-up of 26 months, both groups 
had comparable survival (lymphadenectomy versus no lymphadenectomy: 34 versus 32 months). Similar 
survival was noted for patients who underwent the removal of more or less than 5 pelvic lymph nodes.
Conclusion: Selective lymphadenectomy offers the advantage of improved surgical staging but no 
therapeutic benefit in terms of overall survival.
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Selective lymphadenectomy in endometrial cancer
need for pelvic and para-aortic lymphadenectomy 
to accurately identify lymphatic spread. However, 
it is not well established how this information 
alters prognosis and whether it can guide the use of 
adjuvant therapies. The major concerns regarding 
lymphadenectomy, therefore, include whether it 
is necessary, the extent of lymph node dissection 
required, and whether it can add any therapeutic 
benefit.2-5
 The majority of women with endometrial 
carcinoma are considered low-risk for nodal disease 
at presentation, in which low risk is defined as 
disease limited to the corpus uteri, a histologic grade 
of 1 or 2, endometrioid histology, and myometrial 
invasion of < 50%.6 However, justification for 
performing lymph node dissection is two-fold. 
One reason is to eradicate lymph node disease, if 
present, and the second is to exclude patients with 
negative nodes on histopathology from adjuvant 
therapy, thus sparing them from the adverse effects 
of radiotherapy.
 The present study was conducted to compare 
morbidity and survival data in patients with 
early-stage endometrial cancer who did or did not 
undergo selective lymphadenectomy. Our results 
may be helpful in developing institutional and 
national guidelines for the standard management 
of these patients.
METHODS
 After the approval of our institutional review 
board, we conducted a retrospective analysis of 
all patients who underwent surgical treatment at 
Aga Khan University Hospital, Karachi, Pakistan, 
for suspected early-stage endometrial cancer 
from January 1999 to December 2008. Patients 
who received neoadjuvant chemotherapy or were 
noted to have extra-uterine disease at the time of 
laparotomy were excluded from the study. The 
decision to perform lymphadenectomy or not 
depended on the clinical and radiological assessment 
of the extent of disease, medical comorbidities, and 
New York Heart Association class of the patient. 
This decision was primarily based on the individual 
surgeon’s assessment and preference.
 Selective pelvic lymphadenectomy involved 
removing lymphatic tissue from the anterior 
and medial surfaces of the iliac vessels and from 
the obturator fossa superior to the obturator 
nerve. The decision to remove para-aortic lymph 
nodes was based on radiological assessment, as 
well as the grade of the disease. This procedure 
involved removing the precaval and right and left 
aortic lymphatic tissue to the level of the inferior 
mesenteric artery.
 Medical records for all patients were reviewed, and 
relevant demographic, clinical, surgical, pathologic, 
and follow-up information was acquired. Overall 
survival was compared between the two treatment 
groups (i.e., those who underwent selective 
lymphadenectomy versus those who did not 
undergo this procedure). Perioperative morbidity 
parameters (e.g., duration of surgery, estimated 
blood loss, and organ injury) and postoperative 
complications (e.g., infections, thromboembolism, 
lymphocysts, and lymphoedema) were also 
compared between the two groups.
 SPSS version 19 was used for data recording 
and analysis. Associations between categorical 
covariates were assessed using chi-square tests, 
whereas the t-test was used to assess group 
differences for continuous variables. A two-sided 
p-value of ≤ 0.05 was considered statistically 
significant. Survival curves were estimated using 
the Kaplan–Meier method, and the log-rank test 
was used to compare curves between the groups.
RESULTS
 A total of 180 patients treated for early-stage 
endometrial carcinoma at our institution from 1999 to 
2008 met our eligibility criteria. Of these, 108 patients 
(60%) underwent selective lymphadenectomy 
(Group A) and the remaining 72 patients (40%) did 
not undergo selective lymphadenectomy (Group 
B). In Group A, the median number of lymph nodes 
removed was 9 and the median number of para-
aortic nodes removed was 2.
 The clinico-pathological characteristics of 
patients in both groups are shown in Table-I. These 
characteristics were comparable between groups, 
except for the proportion of patients undergoing 
lymphadenectomy in the different pathologic 
grade groups (p-value < 0.01). Overall, 45% of 
our patients had grade 1 disease and 42% of these 
patients underwent lymphadenectomy. By contrast, 
34% of our patients had grade 2 disease and 79% 
of these patients underwent lymphadenectomy; 
10% of our patients had grade 3 disease and 83% of 
these patients underwent lymphadenectomy. The 
extent of the disease, as assessed by stage (p = 0.06), 
tumour size (p = 0.36), myometrial invasion (p = 
0.27), and lymphovascular invasion (p > 0.99), was 
comparable between the groups. (Table-I)
 Postoperative complications were noted in 21 
patients (11.6%). (Table-II) Of these, 15 patients 
(14%) were in Group A and 6 patients (8%) were 
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in Group B. There were no significant differences 
in medical or surgical complications between 
the groups. The most common complication was 
wound infection, which was observed in 10 patients. 
The median duration of surgery (160 minutes in 
group A versus 141 minutes in group B) and mean 
estimated blood loss (474 mL in group A versus 606 
mL in group B) were also not significantly different 
between groups.
 At a median follow-up of 26 months, 23 adverse 
events were observed. (Table-III). Endometrial 
cancer recurrence was observed in 10 patients (5.5% 
of all 180 patients). Of these, 9 patients were in 
Group A (9/108; 5.5%) and 1 was in the Group B 
(1/72; 1.3%). The most common sites of recurrence 
were the vaginal vault and lungs. Thirteen patients 
died during the study period: 7 patients (3.9%) in 
Group A and 6 patients (3.3%) in Group B.
Uzma Chishti et al.
Table-I: Demographic and Clinical Characteristics of the Study Groups.
 Total(N=180) Lymphadenectomy No Lymphadenectomy P-value
  (Group A)(n=108)      (Group B)(n=72)
Age (years) 57.2 ±10.7 57.6 ± 10.97 56.5±10.39 0.40
Parity
Nullipara 36 (20) 18 (50) 18 (50) 0.187
Any parity 144 (80) 90 (62.5) 54 (37.5)
Body mass index
Non-obese (<25) 32 (18.6) 18 (56) 14 (44) 0.80
Obese (>25) 140 (81.4) 83 (59) 57 (41)
FIGO stage *
Stage I 151 (83.9) 87 (57) 64 (42.4) 0.06
Stage II 10 (5.6) 9 (90.0) 1 (10.0)
Stage III 15 (8.3) 11 (73.3) 4 (27)
Stage IV 4 (2.2) 1 (25) 3 (75) 
FIGO grade
Grade 1 82 (45.6) 34 (41.5) 48 (58.5) < 0.01
Grade 2 61 (33.9) 48 (78.7) 13 (21.3)
Grade 3 18 (10) 15 (83.3) 3 (16.7) 
Tumour size (cm)
< 2 46 (25.7) 24 (52.2) 22 (47.8) 0.36
> 2 132 (73.7) 83 (62.9) 49 (37)
Myometrial invasion
None 18 (10) 11 (61) 7 (38.9) 0.27
Less than half 107 (59.4) 60 (56) 47 (44)
More than half 55 (30.6) 37 (67) 18 (33)
Lymphovascular invasion
No 168 (93.3) 102 (60.7) 66 (39.3) > 0.99
Yes 11 (6.1) 5 (45.5) 6 (54.5)
Number of lymph nodes removed
< 5 31 (29)
> 5 77 (71)
Data are presented as number (percentage) or mean ± standard deviation.
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics.
Table-II: Operation Characteristics and Perioperative Complications.
 Lymphadenectomy No Lymphadenectomy P value
 (Group A) (n=108)     (Group B) (n=72)
Total number of complications 15 (13.9) 6 (8.3) 0.2
Wound infection 8 (7.4) 2 (2.7) 0.7
Thromboembolism 2 (1.8) 1 (1.3) 0.6
Other complications 5 (4.6) 3 (4.1) 0.4
Mean estimated blood loss (mL) 474 606 0.3
Median operating time (min) 160 141 0.05
Data are presented as number or number (percentage).
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 Using the Kaplan-Meier method and log rank 
test, we found that patients in Group A had 
comparable overall survival to those in Group B (32 
months versus 34 months; p = 0.47) (Fig.1). Using 
the same methods, overall survival was found to be 
30 months for those with > 5 pelvic lymph nodes 
removed compared to 37 months for those with < 
5 lymph nodes removed. This difference was not 
statistically significant (p = 0.70).
 Survival was compared by univariate analysis in 
the two treatment arms to determine the effects of 
various covariates, including age, tumour grade, 
extent of myometrial invasion, performance of 
selective lymphadenectomy, and number of lymph 
nodes removed (Table-IV). The results showed that 
none of these factors were associated with survival.
DISCUSSION
 Endometrial cancer is one of the most common 
malignancies in females. The principal method of 
distant spread for this cancer is via the lymphatic 
route. The 1988 International Federation of 
Gynecology and Obstetrics (FIGO) staging system 
emphasizes performing complete surgical staging, 
including lymph node dissection, as the standard 
management for surgical staging of this malignancy. 
In the revised 2009 FIGO staging system, performing 
pelvic and para-aortic lymphadenectomy was noted 
to increase the prognostic value of staging even 
more than the 1988 system.7 According to the most 
recent National Comprehensive Cancer Network 
guidelines, pelvic node dissection is an important 
component for surgical staging, as it helps provide 
important prognostic information.8
 There is a long-standing debate among 
gynaecologic oncologists regarding the benefits 
versus risks of selective lymphadenectomy, 
especially in early-stage endometrial carcinoma.6,9,10 
This debate centres around the impact on survival, 
operating time, infection rates, costs, and risk 
of lymphoedema.9,11 The currently available 
literature does not provide definitive conclusions 
about the role of lymphadenectomy in early-
stage endometrial carcinoma, therefore the issue 
remains controversial. This is reflected in the 
practice patterns of gynaecologic oncologists noted 
in a self-administered survey of members of the 
Society of Gynaecologic Oncology. Only 35% of the 
respondents evaluated both pelvic and para-aortic 
lymph nodes in early-stage disease.12 By contrast, 
a higher percentage (98%) of institutions in Japan 
routinely perform pelvic lymph node dissection in 
endometrial cancer.13
 The risk of nodal involvement in early stage 
disease: In the current study, 5% of patients had 
pelvic lymph node metastases and only 1% had 
Selective lymphadenectomy in endometrial cancer
Table-IV: Univariate analysis of overall survival
for potential prognostic factors.
Prognostic Overall Survival P-value
    factor        (months)
Lymphadenectomy 32 0.47
No lymphadenectomy 34 
Age group (years)
< 45 33.3 0.76
> 45 32.4
Tumour grade
I 38 0.07
II 27
III 18.7
Myometrial invasion
None 26.6 0.81
< 50% 32
> 50% 35.5
Mean number of lymph nodes removed
< 5 37.3 0.70
> 5 29.8
Table-III: Adverse events.
 Lymphadenectomy No Lymphadenectomy
 (Group A) (n=108)     (Group B) (n=72)
Recurrence 9 (5) 1 (0.6)
Death 7 (3.9) 6 (3.3)
Data are presented as number (percentage).
Fig.1: Overall survival comparison 
between the two study groups.
• Lymphadenectomy group.
• No lymphadenectomy group.
para-aortic involvement. These results are similar 
to the rates reported by Cragun et al. (5% pelvic 
and 3% para-aortic node involvement)2 and 
Zuurendonk et al. (5% positive lymph nodes).14 
However, they are considerably lower than the 
9% and 6% rates of positive pelvic and para-
aortic lymph nodes, respectively, reported by the 
Gynecologic Oncology Group study of early-stage 
endometrial cancer patients,15 and the 13.3% rate of 
lymph node involvement reported in a randomized 
trial of systematic lymphadenectomy versus no 
lymphadenectomy.3
 The node-positive patients were not equally 
distributed among the tumour grades in our study. 
The majority of node-positive patients had grade 2 or 
3 histology. Endometrioid histology was observed 
in more than 75% of node-positive patients, 
implying that omission of lymphadenectomy in 
type 1 cancers is not advisable. Because selective 
lymphadenectomy upstaging to stage 3 and 4 was 
observed in 11% of patients in the lymphadenectomy 
group, performing lymphadenectomy affected the 
accuracy of the prognosis.
Morbidity of the surgical procedure: Morbidities 
previously reported to be associated with pelvic and 
para-aortic lymphadenectomy include a significantly 
longer hospital stay, increased mean operative 
blood loss resulting in an increased rate of blood 
transfusions, lymphocysts, and lymphoedema.9,11,16 
In our study, no significant surgical morbidity 
was associated with lymphadenectomy. Mean 
operative blood loss and duration of surgery were 
comparable between the lymphadenectomy and no 
lymphadenectomy groups.
Survival impact of lymphadenectomy: Several 
authors have suggested a beneficial effect of 
lymphadenectomy on survival.2,17-20 Most of these 
were based on retrospective studies, in which 
selection bias and adjuvant treatment of patients 
with nodal metastases may have contributed to the 
improved survival.
 More recently, the results of A Study in the 
Treatment of Endometrial Cancer (ASTEC), a 
randomized trial, have not supported a therapeutic 
benefit of lymphadenectomy.4 However, this trial 
has received much criticism because of its inclusion 
of tumours with non-endometrioid histology, lack 
of a centralized pathologic review process, and 
the use of postoperative radiation that was not 
based on lymph node status.21 Similar results were 
obtained by Dowdy et al., who reported no survival 
benefit of lymphadenectomy in a low-risk group 
based on the Mayo criteria (type 1 histology, grade 
1 or 2, myometrial invasion < 50%, and primary 
tumour diameter £ 2 cm).16 Studies by Hidaka et al., 
Neubauer et al., and Wang et al. also suggested no 
overall survival benefit, but the latter two studies 
showed that lymphadenectomy was helpful in 
identifying patients with risk factors for tailoring 
adjuvant treatment.9,22,23 In the study by Wang et 
al.23, a small subset of patients with stage 1b showed 
improved survival with lymphadenectomy. In 
our study, no survival advantage was observed 
by performing lymphadenectomy in early-stage 
endometrial cancer.
Role of intraoperative assessment regarding 
lymphadenectomy: Excellent disease-free survival, 
over 96%, has been reported by institutions in 
which lymph node dissections have been omitted 
from the management of low-risk endometrial 
cancers.6,9,24,25 Furthermore, three studies have 
been published in which omission of lymph node 
dissection was based on intraoperative assessment 
of tumour size, depth of myometrial invasion, 
and histologic grade.16,25,26 The intraoperative 
assessment was accomplished by gross examination 
and intraoperative frozen section. However, these 
institutions had documented reliable capabilities of 
frozen section assessment of pathologic specimens, 
which may not be available in all hospitals.
 Effect of number of lymph nodes on survival: 
The optimum lymph node count associated with 
improved survival has also been a subject of 
considerable debate among researchers. Removal 
of 10 or more regional lymph nodes has been 
associated with improved survival in early-
stage disease.10 This was one of the controversies 
regarding the ASTEC trial, as 9 or fewer lymph 
nodes were resected in 35% of the patients in that 
study. In the present study, the median number of 
pelvic lymph nodes removed was 9.
CONCLUSION
Selective lymphadenectomy offers the advantage 
of better surgical staging, but it has no therapeutic 
benefit in terms of improving overall or disease-free 
survival. Perioperative morbidities are comparable, 
whether or not selective lymphadenectomy is 
performed. 
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